Results 141 to 150 of about 6,202,104 (299)
Plecstatin inhibits hepatocellular carcinoma tumorigenesis and invasion through cytolinker plectin
The ruthenium‐based metallodrug plecstatin exerts its anticancer effect in hepatocellular carcinoma (HCC) primarily through selective targeting of plectin. By disrupting plectin‐mediated cytoskeletal organization, plecstatin inhibits anchorage‐dependent growth, cell polarization, and tumor cell dissemination.
Zuzana Outla +10 more
wiley +1 more source
Testing for Sufficient Follow-Up in Survival Data With a Cure Fraction. [PDF]
Yuen TP, Musta E.
europepmc +1 more source
Map showing areal distribution of Tertiary rocks, Bates Hole—Shirley Basin area, south-central Wyoming [PDF]
N.M. Denson, E.N. Harshman
openalex +1 more source
Therapeutic strategies for MMAE‐resistant bladder cancer through DPP4 inhibition
We established monomethyl auristatin E (MMAE)‐resistant bladder cancer (BC) cell lines by exposure to progressively increasing concentrations of MMAE in vitro. RNA sequencing showed DPP4 expression was increased in MMAE‐resistant BC cells. Both si‐DPP4 and the DPP4 inhibitor sitagliptin suppressed the viability of MMAE‐resistant BC cells.
Gang Li +10 more
wiley +1 more source
Analysis of Bond Strength of Bioceramic Sealer Following Irrigation with Chlorhexidine. [PDF]
Costa LG +5 more
europepmc +1 more source
Nanosecond infrared laser (NIRL) low‐volume sampling combined with shotgun lipidomics uncovers distinct lipidome alterations in oropharyngeal squamous cell carcinoma (OPSCC) of the palatine tonsil. Several lipid species consistently differentiate tumor from healthy tissue, highlighting their potential as diagnostic markers.
Leonard Kerkhoff +11 more
wiley +1 more source
Assessing the effectiveness of the ZICOMP-Shewhart control chart for monitoring zero-inflated processes. [PDF]
Sattar A +5 more
europepmc +1 more source
Analysis of pressure distribution for free molecule flow in circular tube.
Yuji Kawamura +3 more
openalex +2 more sources
We show that the majority of the 18 analyzed recurrent cancer‐associated ERBB4 mutations are transforming. The most potent mutations are activating, co‐operate with other ERBB receptors, and are sensitive to pan‐ERBB inhibitors. Activating ERBB4 mutations also promote therapy resistance in EGFR‐mutant lung cancer.
Veera K. Ojala +15 more
wiley +1 more source

